Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S.
Decaens T, et al. Among authors: iacobellis a.
Br J Cancer. 2021 Aug;125(3):465. doi: 10.1038/s41416-021-01403-z.
Br J Cancer. 2021.
PMID: 34079081
Free PMC article.
No abstract available.